Cancer Chemother Pharmacol (2014) 73:191–198 DOI 10.1007/s00280-013-2340-5
Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer Seung Woo Yi · Dae Ryong Kang · Kyung Sik Kim · Mi Suk Park · Jinsil Seong · Jeong Youp Park · Seung Min Bang · Si Young Song · Jae Bock Chung · Seung Woo Park
Abstract Purpose There is no established standard treatment for patients with locally advanced biliary tract cancer (BTC). Methods We analyzed the treatment results of locally advanced BTC from Jan 1995 to Dec 2010 at single institution of South Korea with retrospective study. One hundred and seventy-six patients were eligible to investigate the treatment response and toxicity. We treated these patients with 5-fluorouracil (5-FU)- or gemcitabine (GEM)-based concurrent chemoradiotherapy (CCRT) or best supportive care (BSC). The primary end point was overall survival. Results Of these locally advanced BTC patients, 106 patients received CCRT and 70 patients were treated with BSC. The median overall survival was 42.57 weeks (95 % confidence interval [CI], 35.85–49.30) in CCRT group
S. W. Yi · J. Y. Park · S. M. Bang · S. Y. Song · J. B. Chung · S. W. Park (*) Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonsei‑ro, Seodaemun‑gu, Seoul 120‑752, Republic of Korea e-mail: [email protected] D. R. Kang Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Republic of Korea K. S. Kim Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea M. S. Park Department of Diagnostic Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea J. Seong Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea
and 13.29 weeks (95 % CI 10.42–16.15) in BSC group (P
Survival outcome of locally advanced pancreatic cancer has been poor and little is known about prognostic factors of the disease, especially in locally advanced cases treated with concurrent chemoradiation. This study was to analyze overall survival
Concurrent chemoradiotherapy (EBRT + cisplatin) plus intracavitary brachytherapy is the standard of care in patients with advanced cervical cancer. However, a number of patients could not undergone brachytherapy due to massive residual tumor or anato
S-1 chemotherapy is effective against advanced biliary tract cancer. The purpose was to evaluate the efficacy and safety of S-1-based concurrent chemoradiotherapy in patients with advanced biliary tract cancer.
To evaluate whether adjuvant simple hysterectomy after concurrent chemoradiotherapy (CCRT) improves progression-free survival (PFS) compared with current standard care in locally advanced cervical adenocarcinoma (LACAC).
To determine, in the setting of locally advanced pancreatic cancer, the maximum tolerated dose of carbon ion radiation therapy (C-ion RT) and gemcitabine dose delivered concurrently and to estimate local effect and survival.
Cervical cancer is the second most common cause of female cancer death. In Morocco it is the second most common cancer, our department recruits more than 500 patients each year and proximally half of the cases are diagnosed at an advanced stage.